Dafinchi AI

VRTX

Healthcare

Cash and investments totaled $12 billion at quarter-end after $395 million in share repurchases.
Net income was $1.2 billion versus a net loss of $3.3 billion in Q2 2024.
Non-GAAP EPS was $4.52 compared to a loss per share of $12.83 in Q2 2024.
Non-GAAP operating expenses were $1.24 billion, excluding Alpine-related IPR&D expenses, up 24% year-over-year.
Non-GAAP operating income was $1.33 billion compared to a loss of $3.15 billion in Q2 2024.
Non-U.S. revenue rebounded 8% year-over-year with CF growth and CASGEVY contributions.
U.S. revenue grew 14% driven by CF patient demand, CASGEVY, JOURNAVX, and collaboration revenue.
Vertex announced a new $4 billion share repurchase program in addition to the existing $3 billion program.
Vertex delivered $2.96 billion in revenue in Q2 2025, representing 12% growth year-over-year.

CRNX

Healthcare

Approximately 94.2 million shares of common stock were outstanding as of July 29, 2025, with 111.9 million fully diluted shares.
Crinetics Pharmaceuticals reported $1 million in revenue for Q2 2025 from licensing and supply agreements with its Japanese partner SKK.
Net cash used was $77.8 million during the quarter, with a cash balance of $1.2 billion at quarter-end.
Research and development expenses increased to $80.3 million in Q2 from $76.2 million in Q1, reflecting investments in multiple clinical programs.
Selling, general and administrative expenses rose to $49.8 million from $35.5 million, driven by commercial capability building and launch preparations.

Earnings Feed